




# DEFEKTE IN DER ANGEBORENEN IMMUNITÄT ALS URSACHE FÜR INFEKTANFÄLLIGKEIT BEIM ERWACHSENEN

Simon Rothenfuß

Immundefektambulanz für Erwachsene und Abteilung für Klinische Pharmakologie  
Med. Klinik und Poliklinik IV  
Klinikum der Universität München



# AGENDA


---

**Selbst und Fremd: Das Prinzip Mustererkennung in der angeborenen Immunität**

**Herpesenzephalitis – eine genetische Erkrankung des TLR-3 Signalwegs?**

**Pilzabwehr: was passiert bei zu viel pStat1?**





# Relevanz der *Selbst-Fremd* Unterscheidung für das Immunsystem

---

- Abwehr von Mikroben: Bakterien, Viren, Pilzen, Parasiten
- Barriere in der Transplantationsmedizin
- Wunder in der Schwangerschaft
- Krankheitsursache bei Autoimmunerkrankungen/ Allergien
- Schutz vor und möglicher Therapieansatz bei Tumoren



## Prinzipien der *Selbst-Fremd*-Unterscheidung

---

- **Erkennung aller Nicht-Selbst Strukturen**

gigantische Zahl der zu erkennenden Strukturen; Prinzip des adaptiven Immunsystems; verwendet von T- und B-Lymphozyten

- **Erkennen nach dem *missing self*-Prinzip**

man muss nur ein *Selbst*-Merkmal (er)kennen; Prinzip wird von Natürlichen Killer Zellen (NK-Zellen) verwendet

- **Erkennen von molekularen Mustern die mit Pathogenen oder für den Organismus schädlichen Zuständen assoziiert sind;**

begrenzte Anzahl erkannter Muster; von der Evolution selektioniert; Prinzip des angeborenen Immunsystems





TÜBINGEN®

## *Muster-Erkennung der angeborenen Immunität*


---

- **Keimbahnkodierte Rezeptoren**
  - beschränkte Anzahl (durch Evolution selektiert)
- **Erkennung konservierter Strukturen die**
  - mit Pathogenen assoziiert sind (PAMPs)
  - mit zellulärem Schaden assoziiert sind (DAMPs)
  - bei Viren Nukleinsäuren
- **Fremd-Selbst Unterscheidung durch:**
  - Strukturdiskriminierung
  - Ortsdiskriminierung
  - Mengendiskriminierung
- **Toll-like Rezeptoren**



# Wildtyp *Drosophila* larvae

Dorsal




Ventral



**Christiane Nüsslein-Volhard,  
Nobelpreisträgerin für Medizin, 1995**




# mutante *Drosophila* larvae



**Anderson *et al.* Cell 1985; 42: 791-98**

KLINIKUM DER UNIVERSITÄT MÜNCHEN®



**Christiane Nüsslein-Volhard,  
Nobel Laureate (Medicine, 1995)**



Toll




# Klonierung von *Toll*: Homologie zum humanen Interleukin-1 Rezeptor




**Lemaitre et al. Cell 1996; 86: 973-83**

***Aspergillus fumigatus***



# Mutationen im *Toll*-Rezeptor prädisponieren zu Pilzinfektionen

***Jules Hofmann***



*Aspergillus  
fumigatus*

**Lemaitre *et al.* Cell 1996; 86: 973-83**

# Toll-like Rezeptoren


- Bruce Beutler  
Endotoxin resistente Maus C3H/HeJ; genetischer *Screen*  
*identifiziert TLR4*
- Ruslan Medzhnitov (Charles Janeway)  
TLR-4 kontrolliert Ko-stimulation
- Shizuo Akira  
TLR K.O Mäuse







## Nobel Price 2011: Bruce A. Beutler and Jules A. Hoffmann





# Gram-negative Cell Envelope





# AGENDA

---

**Selbst und Fremd: Das Prinzip Mustererkennung in der angeborenen Immunität**

**Herpesenzephalitis – eine genetische Erkrankung des TLR-3 Signalwegs?**

**Pilzabwehr: was passiert bei zu viel pStat1?**






- 60-90 % der Bevölkerung HSV1 oder HSV2 positiv
- Latentes Überleben der Viren in Neuronen
- Herpesschübe ausgelöst durch Triggerfaktoren



# HERPES ENZEPHALITIS



- Herpes Enzephalitis: Inzidenz 2-4 pro 1 Mio Einwohner/pro Jahr
- Primäre Infektion und Reaktivierung
- Selbst bei korrekter Behandlung: Sterblichkeit 20%; bleibende Schäden

# HERPESENZEPHALITIS; HSV 1 UND HSV2

---

- Patienten bekommen eine Herpesenzephalitis – dies wird durch das Virus verursacht. Es ist eine Infektionserkrankung.
- Warum bekommt nicht jeder Patient eine Enzephalitis?





## Jean-Laurent Casanova



- These: „Jede lebensbedrohliche Infektion ist durch einen Immundefekt verursacht “




# HERPES; HSV 1 UND HSV2

---

- Es ist ein DNA Virus.
- HSV Viren triggern eine Vielzahl von Mustererkennungsrezeptoren





# Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity

*by Yiqi Guo, Magali Audry, Michael Ciancanelli, Laia Alsina, Joana Azevedo, Melina Herman, Esperanza Anguiano, Vanessa Sancho-Shimizu, Lazaro Lorenzo, Elodie Pauwels, Paul Bastard Philippe, Rebeca Pérez de Diego, Annabelle Cardon, Guillaume Vogt, Capucine Picard, Zafitsara Zo Andrianirina, Flore Rozenberg, Pierre Lebon, Sabine Plancoulaine, Marc Tardieu, Valérie Doireau, Emmanuelle Jouanguy, Damien Chaussabel, Frederic Geissmann, Laurent Abel, Jean-Laurent Casanova, and Shen-Ying Zhang*


*JEM*  
Volume 208(10):2083-2098  
September 26, 2011

KLINIKUM DER UNIVERSITÄT MÜNCHEN®



JEM


**Compound heterozygous mutations in TLR3 in a child with HSE. (A) Family pedigree with allele segregation.**



Yiqi Guo et al. J Exp Med 2011;208:2083-2098

KLINIKUM DER UNIVERSITÄT MÜNCHEN®

## Fehlende TLR3-Aktivierung in Fibroblasten des Patienten




Yiqi Guo et al. J Exp Med 2011;208:2083-2098

KLINIKUM DER UNIVERSITÄT MÜNCHEN®



JEM

**Mutationen in TLR3, UNC93B1, TRIF, TRAF3, TBK1, IRF3, Stat1, alle involviert in den TLR3-Signalweg, sowie in MAVS wurden in HSE patients beschrieben .**



**Shen-Ying Zhang, and Jean-Laurent Casanova J Exp Med 2015;212:1342-1343**


# TLR3 deficiency in herpes simplex encephalitis

High allelic heterogeneity and recurrence risk

## ABSTRACT


**Objective:** To determine the proportion of children with herpes simplex encephalitis (HSE) displaying TLR3 deficiency, the extent of TLR3 allelic heterogeneity, and the specific clinical features of TLR3 deficiency.

**Methods:** We determined the sequence of all exons of *TLR3* in 110 of the 120 patients with HSE enrolled in our study who do not carry any of the previously described HSE-predisposing mutations of TLR3 pathway genes (*TLR3*, *UNC93B1*, *TRIF*, *TRAF3*, and *TBK1*). All the new mutant TLR3 alleles detected were characterized experimentally in-depth to establish the causal relationship between the genotype and phenotype.





**Figure 1 Five novel TLR3 mutant alleles in 6 unrelated patients with herpes simplex encephalitis(A) Family pedigrees with allele segregation in the 6 families.**



Hye Kyung Lim et al. Neurology 2014;83:1888-1897

## ORIGINAL ARTICLE

# Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis

N Mørk<sup>1</sup>, E Kofod-Olsen<sup>2</sup>, KB Sørensen<sup>1</sup>, E Bach<sup>1</sup>, TF Ørntoft<sup>3</sup>, L Østergaard<sup>1,2</sup>, SR Paludan<sup>4</sup>, M Christiansen<sup>2,5</sup> and TH Mogensen<sup>1,2,4</sup>

Herpes simplex encephalitis (HSE) in children has previously been linked to defects in type I interferon production downstream of Toll-like receptor (TLR)3. In the present study, we used whole-exome sequencing to investigate the genetic profile of 16 adult patients with a history of HSE. We identified novel mutations in IRF3, TYK2 and MAVS, molecules involved in generating innate antiviral immune responses, which have not previously been associated with HSE. Moreover, data revealed mutations in TLR3, TRIF, TBK1 and STAT1 known to be associated with HSE in children but not previously described in adults. All discovered mutations were heterozygous missense mutations, the majority of which were associated with significantly decreased antiviral responses to HSV-1 infection and/or the TLR3 agonist poly(I:C) in patient peripheral blood mononuclear cells compared with controls. Altogether, this study demonstrates novel mutations in the TLR3 signaling pathway in molecules previously identified in children, suggesting that impaired innate immunity to HSV-1 may also increase susceptibility to HSE in adults. Importantly, the identification of mutations in innate signaling molecules not directly involved in TLR3 signaling suggests the existence of innate immunodeficiencies predisposing to HSE beyond the TLR3 pathway.

*Genes and Immunity* (2015) **16**, 552–566; doi:10.1038/gene.2015.46; published online 29 October 2015



**Table 1. Demographic, genetic and medical data on HSE patients included in the study together with overview of identified molecules with mutations**

Patient ID	Age, Gender	Molecule	Transcript ID, Transcript variant, Protein variant	ExAC Frequency <sup>a</sup> , Phred score <sup>b</sup>	CSF findings	MR findings (EEG if performed)	Treatment duration <sup>c</sup>
#1	15 years Female	IRF3	NM_001197122.1, c.854G>A, p.Arg285Gln	0.000066, 21.8	Virus: HSV-1 DNA Leukocytes: 197 <sup>d</sup> Protein: 4.16 <sup>d</sup>	MR: Diffuse severe changes consistent with HSE	21 days
#2	34 years Male	IRF3	NM_001197122.1, c.829G>A, p.Ala277Thr	0.0036, 7.6	Virus: HSV-1 DNA Leukocytes: 92 Protein: 0.97	No MR scan performed Normal EEG	14 days
#3	61 years Male	TYK2	NM_003331.4, c.157G>A, p.Ala53Thr	0.0080, 24.0	Virus: HSV-1 DNA Leukocytes: 52 Protein: 0.73	No MR scan CT: Edema and possible minor infarction at right temporal lobe Control CT: changes consistent with HSE	16 days
#4	24 years Female	MAVS	NM_020746.4, c.371C>T, p.Ala124Val	0.00014, 15.9	Virus: HSV-1 DNA Leukocytes: 550 Protein: 1.01	MR: Cyst in pineal gland, otherwise normal	14 days
#5	73 years Male	TICAM1/TRIF	NM_182919.3, c.1702G>A, p.Ala568Thr	0.0031, 23.6	Virus: HSV-1 DNA Leukocytes: 64 Protein: 0.73	CT with contrast; ischemic areas located at the temporal lobes Later MR scan with similar findings	29 days
#6	69 years Male	TICAM1/TRIF	NM_182919.3, c.749C>T, p.Ser160Phe	0.0024, 8.2	Virus: HSV-2 DNA Leukocytes: 136 Protein: 2.66	MR: Only partly successful, no abnormality observed in temporal lobes. Abnormal EEG	21 days
#7	68 years Male	STAT1	NM_007315.3, c.796G>A, p.Val266Ile	0.0020, 10.5	Virus: HSV-1 DNA Leukocytes: 115 Protein: 0.73	MR: Changes in left temporal cerebral hemisphere consistent with HSE	14 days
#8	65 years Male	STAT1	NM_007315.3, c.796G>A, p.Val266Ile	0.0020, 10.5	Virus: HSV DNA Leukocytes: 22.5 Protein: 0.52	MR: Changes after recent infarction/infection in left temporal region	14 days
#9	58 years Male	TLR3	NM_003265.2, c.889C>G, p.Leu297Val	0.0015, 24.2	Virus: HSV-1 DNA Leukocytes: 40 Protein: 0.59	MR: Signal changes in cortical structures bilateral, also edema. Consistent with HSE	26 days
#10	50 years Female	TBK1	NM_013254.3, c.619A>G, p.Ile207Val	ND, 243	Virus: HSV-2 DNA Leukocytes: 258 Protein: 1.65	MR: Normal CT: Diffuse cerebral edema	14 days
#11	59 years Male	—	—	—	Virus: HSV-1 DNA Leukocytes: 88 Protein: 0.36	MR: Changes in left temporal lobe region	14 days
#12	52 years Male	—	—	—	Virus: HSV-1 DNA Leukocytes: 144 Protein: 0.44	MR: Classical fronto-temporal changes on right side	21 days
#13	40 years Female	—	—	—	Virus: HSV-2 DNA Leukocytes: 150 Protein: 0.75	No MR scan performed	10 days
#14	34 years Male	—	—	—	Virus: HSV-1 DNA Leukocytes: 294	MR: Abnormalities especially in cortex at left temporal lobe	14 days
#15	76 years Male	—	—	—	Virus: HSV-1 DNA Leukocytes: <5 Protein/albumin ratio slightly elevated	Normal MR	14 days
#16	41 years Female	—	—	—	Virus: HSV-1 DNA Leukocytes: 368 Protein: 1.12	No MR scan performed CT with changes in left temporal lobe	21 days

Abbreviations: CSF, cerebrospinal fluid; CT, CAT scan; EEG, electroencephalography; HSE, herpes simplex encephalitis; HSV-1/2, herpes simplex virus type 1/2; MR, magnetic resonance.

<sup>a</sup> Allele frequencies from the ExAC server of 60 000 exomes (ref Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: <http://exac.broadinstitute.org>) (accessed 04, 2015).

<sup>b</sup> CADD software prediction of deleteriousness.

<sup>c</sup> acyclovir 10mg kg<sup>-1</sup> × 3 intravenously.

- 10 of 16 patients show mutations in genes implicated in the TLR3 pathway

Genes and Immunity 2015



Lebensbedrohliche Infektionen  
beruhen auf einem Immundefekt?



# AGENDA

---

**Selbst und Fremd: Das Prinzip Mustererkennung in der angeborenen Immunität**

**Herpesenzephalitis – eine genetische Erkrankung des TLR-3 Signalwegs?**

**Pilzabwehr: was passiert bei zu viel pStat1?**



*Candida* spp.

Commensal  
of human  
gastrointestinal  
tract and vagina



- Disseminated infections
- Mucocutaneous infections (oropharyngeal, skin and nail infections)
- Vaginitis

## Chronische mukokutane Candidose CMC





N Engl J Med 2011;365:54-61.



N-linked mannan  
 $\beta$ -glucan

$\alpha$ -glucan  
Chitin





## STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis

Frank L. van de Veerdonk, M.D., Ph.D., Theo S. Plantinga, Ph.D.,  
Alexander Hoischen, Ph.D., Sanne P. Smeekens, M.Sc.,  
Leo A.B. Joosten, Ph.D., Christian Gilissen, Ph.D., Peer Arts, Ph.D.,  
Diana C. Rosentul, M.Sc., Andrew J. Carmichael, M.D.,  
Chantal A.A. Smits-van der Graaf, M.D., Ph.D., Bart Jan Kullberg, M.D., Ph.D.,  
Jos W.M. van der Meer, M.D., Ph.D., Desa Lilic, M.D., Ph.D.,  
Joris A. Veltman, Ph.D., and Mihai G. Netea, M.D., Ph.D.


JEM

Article

## Gain-of-function human *STAT1* mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis

Luyan Liu,<sup>1</sup> Satoshi Okada,<sup>2</sup> Xiao-Fei Kong,<sup>2</sup> Alexandra Y. Kreins,<sup>2</sup>  
Sophie Cypowyj,<sup>2</sup> Avinash Abhyankar,<sup>2</sup> Julie Toubiana,<sup>3</sup> Yuval Itan,<sup>2</sup>  
Magali Audry,<sup>2</sup> Patrick Nitschke,<sup>4</sup> Cécile Masson,<sup>4</sup> Beata Toth,<sup>9</sup> Jérôme Flatot,<sup>1</sup>  
Mélanie Migaud,<sup>1</sup> Maya Chrabieh,<sup>1</sup> Tatiana Kochetkov,<sup>2</sup> Alexandre Bolze,<sup>1,2</sup>  
Alessandro Borghesi,<sup>1</sup> Antoine Toulon,<sup>3</sup> Julia Hiller,<sup>10</sup> Stefanie Eyerich,<sup>10</sup>  
Kilian Eyerich,<sup>10,11</sup> Vera Gulácsy,<sup>9</sup> Ludmyla Chernyshova,<sup>12</sup> Viktor Chernyshov,<sup>13</sup>  
Anastasia Bondarenko,<sup>12</sup> Rosa María Cortés Grimaldo,<sup>14</sup>  
Lizbeth Blancas-Galicia,<sup>15</sup> Ileana Maria Madrigal Beas,<sup>14</sup> Joachim Roesler,<sup>16</sup>  
Klaus Magdorf,<sup>17</sup> Dan Engelhard,<sup>18</sup> Caroline Thumerelle,<sup>19</sup>  
Pierre-Régis Burgel,<sup>20</sup> Miriam Hoernes,<sup>21</sup> Barbara Drexel,<sup>21</sup> Reinhard Seger,<sup>21</sup>  
Theresia Kusuma,<sup>22</sup> Annette F. Jansson,<sup>22</sup> Julie Sawalle-Belohradsky,<sup>22</sup>  
Bernd Belohradsky,<sup>22</sup> Emmanuelle Jouanguy,<sup>1,2</sup> Jacinta Bustamante,<sup>1</sup>  
Mélanie Bué,<sup>23</sup> Nathan Karin,<sup>24</sup> Gizi Wildbaum,<sup>24</sup> Christine Bodemer,<sup>5</sup>  
Olivier Lortholary,<sup>6</sup> Alain Fischer,<sup>7</sup> Stéphane Blanche,<sup>7</sup> Saleh Al-Muhsen,<sup>24</sup>  
Janine Reichenbach,<sup>21</sup> Masao Kobayashi,<sup>26</sup> Francisco Espinosa Rosales,<sup>15</sup>  
Carlos Torres Lozano,<sup>14</sup> Sara Sebnem Kilic,<sup>27</sup> Matias Oleastro,<sup>28</sup> Amos  
Etzioni,<sup>24</sup> Claudia Traidl-Hoffmann,<sup>10,11</sup> Ellen D. Renner,<sup>22</sup> Laurent Abel,<sup>1,2</sup>  
Capucine Picard,<sup>1,6,8</sup> László Maródi,<sup>9</sup> Stéphanie Boisson-Dupuis,<sup>1,2</sup> Anne Puel,<sup>1</sup>  
and Jean-Laurent Casanova<sup>1,2,7,25</sup>





Huppler et al Arthritis Research & Therapy 2012; 14:217



# ZUSAMMENFASSUNG

---

**Selbst und Fremd: Das Prinzip Mustererkennung in der angeborenen Immunität**

**Herpesenzephalitis – in den meisten Fällen ein Immundefekt zu erwarten**

**Gain of function Mutationen in pStat1 führen zu einer Reduktion von TH17 Zellen und verursachen AD Chronische Mukokutane Candidose (CMC)**



# Vielen Dank für Ihre Aufmerksamkeit !

**Prof. Dr. med. Simon Rothenfusser**  
Immundefektambulanz für Erwachsene  
Rheumaeinheit  
Med. Klinik und Poliklinik IV  
Klinikum der Universität München  
Pettenkoferstrasse 8a  
80336 München

